Cellular and T cell engager Immunotherapy
External control analysis for KarMMa-3: idecabtagene vicleucel (ide-cel) vs real-world standard of care (RW SoC; COTA) for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Hans C. Lee, MD
Associate Professor & Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Houston, Texas, United States